Alessandro Spirito1, MD; Dipti Itchhaporia2, MD; Samantha Sartori1, PhD; Edoardo Camenzind3, MD; Alaide Chieffo4, MD; George D. Dangas1, MD, PhD; Soren Galatius5, MD; Raban V. Jeger6, MD; David E. Kandzari7, MD; Adnan Kastrati8, MD; Hyo-Soo Kim9,10,11, MD; Takeshi Kimura12, MD; Martin B. Leon13, MD; Laxmi S. Mehta14, MD; Ghada W. Mikhail15, MD; Marie-Claude Morice16, MD; Johny Nicolas1, MD, MSc; Brunna Pileggi1,17, MD; Patrick W. Serruys18, MD, PhD; Pieter C. Smits19, MD; P. Gabriel Steg20, MD, PhD; Gregg W. Stone1, MD; Marco Valgimigli21,22, MD, PhD; Birgit Vogel1, MD; Clemens von Birgelen23,24, MD, PhD; Giora Weisz25, MD; William Wijns26, MD; Stephan Windecker27, MD; Roxana Mehran1, MD
1. The Zena and Michael A. Wiener Cardiovascular Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; 2. Hoag Memorial Hospital Presbyterian, Newport Beach, CA, USA; 3. Institut Lorrain du Coeur et des Vaisseaux (ILCV), Centre Hospitalier Régional Universitaire Nancy-Brabois, Vandoeuvre-lès-Nancy, France; 4. Division of Cardiology, San Raffaele Hospital, Milan, Italy; 5. Bispebjerg University Hospital, Copenhagen, Denmark; 6. Triemli Hospital, Zurich, Switzerland; 7. Piedmont Heart Institute, Atlanta, GA, USA; 8. Deutsches Herzzentrum München, Technische Universität München, Munich, Germany and DZHK (German Center for Cardiovascular Research), partner site Munich Heart Alliance, Munich, Germany; 9. Research Institute, Seoul National University Hospital, Seoul, Republic of Korea; 10. Strategic Center of Cell & Bio Therapy, Seoul National University Hospital, Seoul, Republic of Korea; 11. Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, and College of Medicine and College of Pharmacy, Seoul National University, Seoul, Republic of Korea; 12. Department of Cardiovascular Medicine, Graduate School of Medicine, Kyoto University, Kyoto, Japan; 13. Department of Medicine, Columbia University Medical Center, New York, NY, USA; 14. Division of Cardiovascular Medicine, The Ohio State University Wexner Medical Center, Columbus, OH, USA; 15. Imperial College Healthcare NHS Trust, London, UK; 16. Department of Cardiology, Institut Hospitalier Jacques Cartier, Ramsay Générale de Santé, Massy, France; 17. Department of Cardiopneumonology, Heart Institute of the University of São Paulo, São Paulo, Brazil; 18. University of Galway, Galway, Ireland; 19. Department of Cardiology, Maasstad Hospital, Rotterdam, the Netherlands; 20. Département Hospitalo-Universitaire FIRE, AP-HP, Hôpital Bichat, Paris, France; 21. Istituto Cardiocentro Ticino, Lugano, Switzerland; 22. Università della Svizzera italiana (USI), Lugano, Switzerland; 23. Department of Health Technology and Services Research, Technical Medical Centre, Faculty of Behavioural, Management, and Social Sciences, University of Twente, Enschede, the Netherlands; 24. Thoraxcentrum Twente, Medisch Spectrum Twente, Enschede, the Netherlands; 25. Columbia University Medical Center and Cardiovascular Research Foundation, New York, NY, USA; 26. University of Galway, Saolta University Healthcare Group, Galway, Ireland; 27. Department of Cardiology, Inselspital, University of Bern, Bern, Switzerland; 27. Department of Cardiology, Inselspital, University of Bern, Bern, Switzerland
Background: For women undergoing drug-eluting stent (DES) implantation, the individual and combined impact of chronic kidney disease (CKD) and diabetes mellitus (DM) on outcomes is uncertain.
Aims: We sought to assess the impact of CKD and DM on prognosis in women after DES implantation.
Methods: We pooled patient-level data on women from 26 randomised controlled trials comparing stent types. Women receiving DES were stratified into 4 groups based on CKD (defined as creatine clearance <60 mL/min) and DM status. The primary outcome at 3 years after percutaneous coronary intervention was the composite of all-cause death or myocardial infarction (MI); secondary outcomes included cardiac death, stent thrombosis and target lesion revascularisation.
Results: Among 4,269 women, 1,822 (42.7%) had no CKD/DM, 978 (22.9%) had CKD alone, 981 (23.0%) had DM alone, and 488 (11.4%) had both conditions. The risk of all-cause death or MI was not increased in women with CKD alone (adjusted hazard ratio [adj. HR] 1.19, 95% confidence interval [CI]: 0.88-1.61) nor DM alone (adj. HR 1.27, 95% CI: 0.94-1.70), but was significantly higher in women with both conditions (adj. HR 2.64, 95% CI: 1.95-3.56; interaction p-value <0.001). CKD and DM in combination were associated with an increased risk of all secondary outcomes, whereas alone, each condition was only associated with all-cause death and cardiac death.
Conclusions: Among women receiving DES, the combined presence of CKD and DM was associated with a higher risk of the composite of death or MI and of any secondary outcome, whereas alone, each condition was associated with an increase in all-cause and cardiac death.
No account yet? Create my pcr account
Sign up for free!
Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases
deathdiabetesdrug-eluting stentmiscellaneousrenal insufficiency
Read next article
Transcatheter aortic valve implantation with the Evolut platform for bicuspid aortic valve stenosis: the international, multicentre, prospective BIVOLUTX registry